Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04515394
Title Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors EMD Serono Research & Development Institute, Inc.

colorectal cancer


Cetuximab + Tepotinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | BEL

Additional content available in CKB BOOST